Jean Rommelaere

Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice.

Specific interaction of the nonstructural protein NS1 of minute virus of mice (MVM) with [ACCA](2) motifs in the centre of the right-end MVM DNA palindrome induces hairpin-primed viral DNA replication.

The NS2 proteins of parvovirus minute virus of mice are required for efficient nuclear egress of progeny virions in mouse cells.

Regulation of minute virus of mice NS1 replicative functions by atypical PKClambda in vivo.

Production of recombinant H1 parvovirus stocks devoid of replication-competent viruses.

Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells.

Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells.

Modulation of minute virus of mice cytotoxic activities through site-directed mutagenesis within the NS coding region.

The human small glutamine-rich TPR-containing protein is required for progress through cell division.

Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing.

Vectors based on autonomous parvoviruses: novel tools to treat cancer?

Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases.

Cancer gene therapy through autonomous parvovirus--mediated gene transfer.

Selective alterations of the host cell architecture upon infection with parvovirus minute virus of mice.

The infectivity and lytic activity of minute virus of mice wild-type and derived vector particles are strikingly different.

Expression profiling of human hepatoma cells reveals global repression of genes involved in cell proliferation, growth, and apoptosis upon infection with parvovirus H-1.

B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression.

Changes in gene expression profiles induced by parvovirus H-1 in human gastric cancer cells.

Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells.

Phosphorylation on Ser106 modulates the cellular functions of the SHOX homeodomain protein.

Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line.

NS1 interaction with CKII alpha: novel protein complex mediating parvovirus-induced cytotoxicity.

Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells.

Human SGT interacts with Bag-6/Bat-3/Scythe and cells with reduced levels of either protein display persistence of few misaligned chromosomes and mitotic arrest.

Humoral immune responses against minute virus of mice vectors.

MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells.

Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells.

Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.

A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells.

Parvovirus interference with intracellular signalling: mechanism of PKCeta activation in MVM-infected A9 fibroblasts.

Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity.

Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein.

Vesicular egress of non-enveloped lytic parvoviruses depends on gelsolin functioning.

Viral proteins killing tumor cells: new weapons in the fight against cancer.

Biophysical and biochemical characterization of a liposarcoma-derived recombinant MnSOD protein acting as an anticancer agent.

Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.

Ezrin-radixin-moesin family proteins are involved in parvovirus replication and spreading.

Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.

SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.

Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism.

Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells.

Oncolytic parvoviruses as cancer therapeutics.

Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.

Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.

Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species.

Enhancement of NK cell antitumor responses using an oncolytic parvovirus.

Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.

Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.

The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo.

Regression of glioma in rat models by intranasal application of parvovirus h-1.

Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.

Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.

Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.

Activation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirus.

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.